Beate Stern
Oprichter bij Uni Targeting Research AS
Profiel
Beate Stern is the founder of Uni Targeting Research AS, which was founded in 2001.
She held the title of Chief Scientific Officer at the company.
Currently, Dr. Stern is working as an Associate Professor at the University of Bergen.
In the past, she worked as a Principal at the Max-Planck-Institute for Molecular Genetics.
Actieve functies van Beate Stern
| Bedrijven | Functie | Begin |
|---|---|---|
Uni Targeting Research AS
 Uni Targeting Research AS BiotechnologyHealth Technology Uni Targeting Research AS is a holding company that provides the biopharmaceutical industry with tools and services for mammalian cell-line based development procedures and production processes. It offers upstream solutions to reduce complementary deoxyribonucleic acid and mammalian cell-line based timelines and increase protein production yields. Its technology enables both enhanced synthesis/secretion of naturally secreted proteins, and secretion of intracellular proteins. Its services include vector improvement, tailor-made vectors, and tool proteins. The company was founded by Ian Fraser Pryme, John E. Hesketh, Albert Tauler, and Beate Stern in 2001 and is headquartered in Bergen, Norway. | Oprichter | 28-07-2009 |
| University of Bergen | Corporate Officer/Principal | - |
Eerdere bekende functies van Beate Stern
| Bedrijven | Functie | Einde |
|---|---|---|
| Max-Planck-Institute for Molecular Genetics | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Uni Targeting Research AS
Uni Targeting Research AS BiotechnologyHealth Technology Uni Targeting Research AS is a holding company that provides the biopharmaceutical industry with tools and services for mammalian cell-line based development procedures and production processes. It offers upstream solutions to reduce complementary deoxyribonucleic acid and mammalian cell-line based timelines and increase protein production yields. Its technology enables both enhanced synthesis/secretion of naturally secreted proteins, and secretion of intracellular proteins. Its services include vector improvement, tailor-made vectors, and tool proteins. The company was founded by Ian Fraser Pryme, John E. Hesketh, Albert Tauler, and Beate Stern in 2001 and is headquartered in Bergen, Norway. | Health Technology |
